Exploring novel therapeutic options in T-LGL, including epigenetic modulation: a case report.
Miftakhova
Regina
R
Sandberg
Tove
T
Longno
Sharon
S
Bjork
Peter
P
Bjornsson
Sven
S
Lazarevic
Vladimir L J
VL
Persson
Jenny
J
Bredberg
Anders
A
D015703:Antigens, CD / Q000032:analysis; D002455:Cell Division; D003165:Complement System Proteins / Q000502:physiology; D018899:CpG Islands; D019175:DNA Methylation; D047628:Estrogen Receptor alpha / Q000235:genetics; D019942:Genes, p16; D015789:HLA-A2 Antigen / Q000032:analysis; D006801:Humans; D054066:Leukemia, Large Granular Lymphocytic / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000494:pharmacology; D011401:Promoter Regions, Genetic; D018168:Receptors, Retinoic Acid / Q000235:genetics; D000072482:Retinoic Acid Receptor alpha; D013601:T-Lymphocytes / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D015703:Antigens, CD; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D015789:HLA-A2 Antigen; D016853:Muromonab-CD3; C000607071:RARA protein, human; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D003165:Complement System Proteins